Breaking News Instant updates and real-time market news.

PTLA

Portola Pharmaceuticals

$37.77

0.14 (0.37%)

, CELG

Celgene

$91.23

0.92 (1.02%)

08:04
08/09/18
08/09
08:04
08/09/18
08:04

Portola Pharmaceuticals names Ernie Meyer as CHRO

Portola Pharmaceuticals (PTLA) announced the appointment of Ernie Meyer as executive vice president and chief human resources officer, effective August 20. As a member of the Executive Committee, Mr. Meyer will report to John T. Curnutte, M.D., Ph.D., interim co-president of Portola and head of research and development, with responsibility for leading the development and execution of the Company's global human resources strategy. Meyer joins Portola from Celgene (CELG), where he spent more than 13 years in positions of increasing scope and responsibility. Most recently, Mr. Meyer served as executive vice president of human resources & corporate services.

PTLA

Portola Pharmaceuticals

$37.77

0.14 (0.37%)

CELG

Celgene

$91.23

0.92 (1.02%)

  • 09

    Aug

  • 25

    Aug

  • 29

    Oct

PTLA Portola Pharmaceuticals
$37.77

0.14 (0.37%)

05/07/18
SBSH
05/07/18
NO CHANGE
Target $64
SBSH
Buy
Portola Pharmaceuticals price target raised to $64 from $58 at Citi
Citi analyst Yigal Nochomovitz raised his price target for Portola Pharmaceuticals to $64 following the FDA approval of Andexxa. The analyst keeps a Buy rating on the shares.
05/07/18
OPCO
05/07/18
NO CHANGE
Target $80
OPCO
Outperform
Portola Pharmaceuticals price target raised to $80 from $67 at Oppenheimer
Oppenheimer analyst Jay Olson raised his price target for Portola Pharmaceuticals to $80 from $67 after AndexXa received FDA approval as the first and only antidote indicated for patients treated with rivaroxaban and apixaban when reversal is needed in the case of life-threatening or uncontrolled bleeding. The analyst believes potential drivers of upside include AndexXa likely expanding factor Xa use and label extensions, U.S. approval of Gen2 manufacturing to expand capacity, European CHMP opinion in Q4 and cerdulatinib data at ASCO. Olson reiterates an Outperform rating on the shares.
05/07/18
MSCO
05/07/18
NO CHANGE
Target $46
MSCO
Equal Weight
Portola price target raised to $46 from $31 at Morgan Stanley
Morgan Stanley analyst Matthew Harrison raised his price target on Portola Pharmaceuticals to $46 following the FDA approval of AndexXa, calling it a significant positive. However, he maintains an Equal Weight rating on the shares, as he expects the stock to trade with the market given the limited launch will not allow investors to gauge true demand until 2019.
06/14/18
SBSH
06/14/18
NO CHANGE
SBSH
Buy
Portola not planning sale despite CEO transition, says Citi
Citi analyst Yigal Nochomovitz asked Portola Pharmaceuticals if the CEO transition means the company is potentially up for sale. Management emphasized that the CEO transition should not be interpreted as meaning they are planning to sell the company, Nochomovitz tells investors in a research note. He points out that management reiterated they are working towards advancing the company commercially. With two approved drugs in thrombosis, Portola views itself as well positioned to attract new talent to continue to build its sales force, Nochomovitz writes after speaking to the company. He keeps a Buy rating on the shares.
CELG Celgene
$91.23

0.92 (1.02%)

07/24/18
JPMS
07/24/18
NO CHANGE
JPMS
Overweight
Celgene positive headline streak continues, says JPMorgan
Last night's positive topline data for Revlimid plus Rituxan in relapsed/refractory indolent lymphoma is a "clear win" at a time when Celgene "really needed a string of favorable events," JPMorgan analyst Cory Kasimov tells investors in a research note titled "Positive Headline Streak Continues with AUGMENT." The analyst sees this indication as a "meaningful" near-term sales opportunity for the franchise prior to loss of exclusivity, potentially $600M in the U.S. alone. He expects the positive data to "modestly bolster sentiment" into Celgene's Q2 results. Kasimov keeps an Overweight rating on the shares.
07/26/18
PIPR
07/26/18
NO CHANGE
Target $95
PIPR
Neutral
Longer term concerns remain despite 'impressive' Q2 for Celgene, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond reiterates a Neutral rating and $95 price target for Celgene despite a "solid" Q2 results. With an "impressive" $110M Revlimid beat this quarter and $200M guidance increase, Celgene continues its pattern of strong Q2 performance, he notes. But despite this commercial execution, Raymond's concerns with respect to the company's ability to diversify away from Revlimid remain and he continues to prefer the sidelines on this name.
07/30/18
RHCO
07/30/18
NO CHANGE
Target $101
RHCO
Hold
Celgene price target raised to $101 from $96 at SunTrust
SunTrust analyst Yatin Suneja raised his price target on Celgene to $101 after its Q2 results, saying the company saw "good performances from all core products except Otezla and Abraxan", while its updated FY18 outlook also reflects its larger than anticipated share buyback. Suneja further notes that Celgene's pipeline assets ozanimod, fedratinib, luspatercept and the CAR-T programs are all progressing towards filings, which may help the company diversify its pipeline away from Revlimid. The analyst also keeps his Hold rating, noting that any near-term contribution from its extensive pipeline are likely to be limited.
08/08/18
RBCM
08/08/18
NO CHANGE
Target $110
RBCM
Outperform
RBC Capital revisits idea of Celgene going private after Tesla proposal
Following yesterday's news that Tesla (TSLA) CEO Elon Musk would like to see his company go private, RBC analyst Brian Abrahams revisited his prior analysis of whether Celgene (CELG) should go private in order to better capture the medium-term value of future Revlimid cash flows not being appreciated by public markets and avoid volatility as it transitions to a post-Revlimid business model. Though acknowledging that the two companies are in completely different industries, he thinks the example of Musk shows that performing such a transaction on a large company "may not be completely unrealistic," Abrahams said. Such an LBO, or perhaps more likely an acquisition by a larger pharmaceutical company, could possibly help capture more value from Celgene's commercial and pipeline products, concludes Abrahams, who has an Outperform rating and $110 price target on Celgene shares.

TODAY'S FREE FLY STORIES

KFS

Kingsway Financial

$2.30

-0.14 (-5.74%)

19:48
04/19/19
04/19
19:48
04/19/19
19:48
Hot Stocks
Kingsway Financial announces receipt of notification letter from NYSE »

Kingsway Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AWK

American Water

$104.63

2.32 (2.27%)

19:46
04/19/19
04/19
19:46
04/19/19
19:46
Hot Stocks
American Water signs contract to acquire East Pasadena Water Company »

California American…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 10

    May

FSNN

Fusion

$0.24

0.0048 (2.01%)

19:45
04/19/19
04/19
19:45
04/19/19
19:45
Hot Stocks
Fusion sees being delisted following receipt of Nasdaq delisting notice »

Fusion announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 30

    May

PSA

Public Storage

$217.43

0.81 (0.37%)

19:42
04/19/19
04/19
19:42
04/19/19
19:42
Hot Stocks
Public Storage announces change of Chief Legal Officer »

Public Storage announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 02

    May

  • 04

    Jun

V

Visa

$160.14

-0.33 (-0.21%)

19:40
04/19/19
04/19
19:40
04/19/19
19:40
Hot Stocks
Visa board elects Visa CEO Al Kelly as Chair »

Visa announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 09

    May

  • 29

    May

  • 05

    Jun

NAVB

Navidea

$0.17

0.0001 (0.06%)

19:39
04/19/19
04/19
19:39
04/19/19
19:39
Hot Stocks
Navidea announces one-for-twenty reverse stock split »

Navidea…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TISA

Top Image Systems

$0.84

-0.0069 (-0.81%)

19:37
04/19/19
04/19
19:37
04/19/19
19:37
Hot Stocks
Top Image sees voluntarily delisting to be complete before Nasdaq deadline »

Top Image Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCPT

Four Corners Property Trust

$28.17

0.49 (1.77%)

19:33
04/19/19
04/19
19:33
04/19/19
19:33
Hot Stocks
Four Corners Property Trust acquires restaurant properties for $2.6M »

Four Corners Property…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

PRK

Park National

$93.98

-2.72 (-2.81%)

19:32
04/19/19
04/19
19:32
04/19/19
19:32
Earnings
Park National reports Q1 EPS $1.62, two estimates $1.61 »

Commercial loans grew…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 29

    May

STNE

StoneCo

$26.50

-8.25 (-23.74%)

19:29
04/19/19
04/19
19:29
04/19/19
19:29
Hot Stocks
StoneCo says latest incentive offers from competitors don't change strategy »

StoneCo released a CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

GPIC

Gaming Partners

$13.09

(0.00%)

19:24
04/19/19
04/19
19:24
04/19/19
19:24
Hot Stocks
Gaming Partners sees acquisition by Angel closing on May 1 »

Gaming Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCHW

Charles Schwab

$45.57

-0.53 (-1.15%)

17:04
04/19/19
04/19
17:04
04/19/19
17:04
Conference/Events
Charles Schwab to hold a webcast »

Management holds a 2019…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 15

    May

12:45
04/19/19
04/19
12:45
04/19/19
12:45
General news
Breaking General news story  »

Week of 4/19 Baker-Hughes…

MMNFF

MedMen

$0.00

(0.00%)

11:13
04/19/19
04/19
11:13
04/19/19
11:13
Hot Stocks
MedMen announces resignations of COO and General Counsel »

MedMen Enterprises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TKC

Turkcell

$5.49

-0.175 (-3.09%)

11:08
04/19/19
04/19
11:08
04/19/19
11:08
Hot Stocks
Turkcell sees conclusion of $4.2B lawsuit against MTN this year »

The following statement…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCCY

1st Constitution Bancorp

$18.07

-0.14 (-0.77%)

11:05
04/19/19
04/19
11:05
04/19/19
11:05
Earnings
1st Constitution Bancorp reports Q1 EPS 39c, two estimates 36c »

Robert Mangano, President…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QUMU

Qumu

$2.83

-0.035 (-1.22%)

11:03
04/19/19
04/19
11:03
04/19/19
11:03
Hot Stocks
Qumu announces death of director Thomas Madison »

Qumu Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 09

    May

FAT

Fat Brands

$5.15

0.065 (1.28%)

10:54
04/19/19
04/19
10:54
04/19/19
10:54
Hot Stocks
Fat Brands announces development of Fatburger concept in Albuquerque »

FAT Brands announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRTG

Heritage Insurance

$14.32

0.25 (1.78%)

10:52
04/19/19
04/19
10:52
04/19/19
10:52
Hot Stocks
Heritage Insurance announces preliminary Q1 catastrophe losses of $15.4M »

Heritage Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

COTY

Coty

$11.27

0.02 (0.18%)

10:48
04/19/19
04/19
10:48
04/19/19
10:48
Hot Stocks
Coty notes extension of tender offer by affiliate of JAB Holding Company »

Coty notes the extension…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTES

NetEase

$265.88

-2.34 (-0.87%)

10:45
04/19/19
04/19
10:45
04/19/19
10:45
Hot Stocks
NetEase announces music license agreement with Nippon Columbia »

NetEase Cloud Music…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:10
04/19/19
04/19
09:10
04/19/19
09:10
General news
Today's U.S. housing report revealed March declines »

Today's U.S. housing…

08:45
04/19/19
04/19
08:45
04/19/19
08:45
General news
U.S. housing starts fell 0.3% to 1.139 M in March »

U.S. housing starts fell…

08:15
04/19/19
04/19
08:15
04/19/19
08:15
General news
Housing Starts to be reported at 08:30 »

March Housing Starts will…

08:15
04/19/19
04/19
08:15
04/19/19
08:15
General news
Housing Starts Permits to be reported at 08:30 »

March Housing Starts…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.